Honokiol suppresses lung tumorigenesis by targeting EGFR and its downstream effectors

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Epidermal growth factor receptor (EGFR) deregulation is common in pre-malignant lung epithelium, driving cancer development.
• Targeting EGFR is a key strategy for lung cancer treatment and prevention.

Purpose of the Study:

• To investigate the anti-cancer effects of honokiol, a compound from Magnolia officinalis, on EGFR-driven lung cancer.
• To evaluate honokiol's efficacy alone and in combination with erlotinib, and its potential in a preclinical lung tumor model.

Main Methods:

• In vitro studies on EGFR-overexpressing lung cancer cells assessing proliferation, apoptosis, and protein expression (phospho-EGFR, phospho-Akt, phospho-STAT3).
• Molecular docking to determine honokiol's binding to EGFR tyrosine kinase domain.
• In vivo mouse lung tumor bioassay using intranasal liposomal honokiol.
• Combination treatment with honokiol and erlotinib on sensitive and resistant cell lines.

Main Results:

• Honokiol suppressed proliferation (up to 93%) and induced apoptosis (up to 61%) in EGFR-overexpressing lung cells, linked to downregulation of key signaling proteins.
• Honokiol demonstrated stronger anti-proliferative and pro-apoptotic activity than erlotinib in vitro.
• Honokiol sensitized erlotinib-resistant cells to erlotinib treatment.
• Liposomal honokiol reduced lung tumor size and multiplicity by 49% in mice, decreasing EGFR signaling.

Conclusions:

• Honokiol exhibits potent anti-lung cancer activity by targeting EGFR signaling pathways.
• Honokiol is a promising therapeutic candidate for preventing and treating EGFR-driven lung tumors.
• Honokiol can overcome resistance to existing EGFR inhibitors like erlotinib.